Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease

Pediatric Cardiology

Volumn 31, Issue 1, 2010, Pages 90-95

  Chang, Ruey Kang R ^a   Chen, Alex Y ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Congenital heart disease; Palivizumab; RSV prophylaxis

Indexed keywords

PALIVIZUMAB;

ARTICLE; BRONCHIOLITIS; CHEMOPROPHYLAXIS; CHILD; CONGENITAL HEART DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; HEMODYNAMICS; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SENSITIVITY ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BRONCHIOLITIS; CALIFORNIA; CASE-CONTROL STUDIES; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; DRUG COSTS; HEART DEFECTS, CONGENITAL; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 75549083356     PISSN: 01720643     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00246-009-9577-0     Document Type: Article

References (18)

1. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn 1998 Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV Pediatrics 102 1211 1216 10.1542/peds.102.5.1211 (Pubitemid 28511733)
2. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn 2003 Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections Pediatrics 112 1442 1446 10.1542/peds.112.6.1442 (Pubitemid 37523437)
3. CM Booth WJ Mackillop 2008 Translating new medical therapies into societal benefit: the role of population-based outcome studies JAMA 300 2177 2179 10.1001/jama.300.18.2177 1:CAS:528:DC%2BD1cXhtlOrurrO 19001630
4. SA Cohen R Zanni A Cohen M Harrington P Vanveldhuisen ML Boron 2008 Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry Pediatr Cardiol 29 382 387 10.1007/s00246-007-9039-5 17926087
5. NO Elhassan ME Sorbero CB Hall TP Stevens AW Dick 2006 Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease Arch Pediatr Adolesc Med 160 1070 1076 10.1001/archpedi.160.10.1070 17018467 (Pubitemid 44520638)
6. TF Feltes AK Cabalka HC Meissner FM Piazza DA Carlin FH Top Jr EM Connor HM Sondheimer 2003 Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease J Pediatr 143 532 540 10.1067/S0022-3476(03)00454-2 1:CAS:528:DC%2BD3sXot1Gktbw%3D 14571236 (Pubitemid 37352516)
7. JL Hall BZ Katz 2005 Cost of influenza hospitalization at a tertiary care children's hospital and its impact on the cost-benefit analysis of the recommendation for universal influenza immunization in children age 6 to 23 months J Pediatr 147 807 811 10.1016/j.jpeds.2005.06.031 16356436 (Pubitemid 41774838)
8. S Joffe GT Ray GJ Escobar SB Black TA Lieu 1999 Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants Pediatrics 104 419 427 10.1542/peds.104.3.419 1:STN:280:DyaK1MvgtVylsw%3D%3D 10469764 (Pubitemid 29424659)
9. S Kamal-Bahl J Doshi J Campbell 2002 Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review Arch Pediatr Adolesc Med 156 1034 1041 12361451
10. A Meberg AL Bruu 2006 Respiratory syncytial virus infections in congenital heart defects-hospitalizations and costs Acta Paediatr 95 404 406 10.1080/08035250500447944 16720485 (Pubitemid 43739064)
11. MJ Nuijten W Wittenberg M Lebmeier 2007 Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis Pharmacoeconomics 25 55 71 10.2165/00019053-200725010-00006 17192118
12. X Saez-Llorens E Castano D Null J Steichen PJ Sanchez O Ramilo FH Top Jr E Connor 1998 Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group Pediatr Infect Dis J 17 787 791 10.1097/00006454-199809000-00007 1:STN:280: DyaK1cvltFSnsA%3D%3D 9779762 (Pubitemid 28475545)
13. DK Shay RC Holman RD Newman LL Liu JW Stout LJ Anderson 1999 Bronchiolitis-associated hospitalizations among US children, 1980-1996 JAMA 282 1440 1446 10.1001/jama.282.15.1440 1:STN:280:DC%2BD3c%2FgsVSqsA%3D%3D 10535434 (Pubitemid 29493797)
14. EA Simoes HM Sondheimer FH Top Jr HC Meissner RC Welliver AA Kramer JR Groothuis 1998 Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group J Pediatr 133 492 499 10.1016/S0022-3476(98)70056-3 1:CAS:528:DyaK1cXntFSquro%3D 9787686 (Pubitemid 28465374)
15. The IMpact-RSV Study Group 1998 Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants Pediatrics 102 531 537 10.1542/peds.102.3.531 (Pubitemid 28409250)
16. The PREVENT Study Group 1997 Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis Pediatrics 99 93 99 10.1542/peds.99.1.93 (Pubitemid 27136610)
17. S Wegner JJ Vann G Liu P Byrns C Cypra W Campbell A Stiles 2004 Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program Pediatrics 114 1612 1619 10.1542/peds.2004-0959 15574623 (Pubitemid 41754927)
18. LE Yount WT Mahle 2004 Economic analysis of palivizumab in infants with congenital heart disease Pediatrics 114 1606 1611 10.1542/peds.2004-0224 15574622 (Pubitemid 41754926)